Structure · schematic
Peptide chain of 39 amino acids · GLP-1-Analog
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid (shown truncated).
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- Retatrutide is a triple agonist at GIP, GLP-1 and glucagon receptors (GGG agonist).
- The additional activation of the glucagon receptor compared with dual GIP/GLP-1 agonists such as tirzepatide is intended to increase basal metabolic rate and intensify hepatic fat metabolism.
- Eli Lilly developed the peptide with the aim of addressing all three incretin receptors simultaneously.
- The selectivity and ratio of receptor activation were chosen so as to minimise hyperglycaemia from glucagon agonism.
Research status
- Retatrutide is in clinical development.
- A Phase II study (2023, n=338) investigated various doses over 24 weeks in obesity and observed weight reductions of up to 17.5% of baseline weight — numerically above the values observed for semaglutide or tirzepatide in comparable Phase II studies.
- Phase III studies (the TRIUMPH programme) have been started; results are pending.
- Long-term safety and cardiovascular endpoints have not been conclusively investigated.
Evidence level
Cited studies
Known risks
- 01Safety profile not conclusively established — no completed Phase III data
- 02Gastrointestinal side effects (nausea, vomiting, diarrhoea) frequently described in Phase II studies
- 03Glucagon agonism could promote blood-sugar instability in diabetics
- 04Heart rate increase possible under glucagon agonism
- 05Gallbladder complications with rapid weight loss
- 06Interactions with other blood-sugar-lowering medications not fully characterised
- 07No long-term safety data available
Frequently asked questions
What is Retatrutid?
Retatrutide is a triple agonist at GIP, GLP-1 and glucagon receptors (GGG agonist).
What type of peptide is Retatrutid?
Retatrutid belongs to the GLP-1 analog class.
Is Retatrutid legal in Germany?
Retatrutid is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy Retatrutid?
Peptica sells nothing and names no sources. Retatrutid is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is Retatrutid banned in sport (WADA)?
Retatrutid is currently not on the WADA Prohibited List.
What are the known risks of Retatrutid?
Documented risks include: Safety profile not conclusively established — no completed Phase III data; Gastrointestinal side effects (nausea, vomiting, diarrhoea) frequently described in Phase II studies. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is Retatrutid?
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
What is the molecular weight of Retatrutid?
Retatrutid has a molar mass of about 4731.33 Da, with a plasma half-life of ~6 days.
Which peptides are related to Retatrutid?
Closely related entries: Semaglutid, Tirzepatid. A direct side-by-side comparison is available via the compare function.
Related entries
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature.
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 1 May 2026
Legal assessment
Retatrutide does not yet have market approval in the EU, Germany or Switzerland. Phase III studies are ongoing; a possible approval submission to the EMA and FDA is expected in 2026/2027 at the earliest. Obtaining it as a research chemical outside clinical studies is illegal and carries considerable safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.